Cheng AL - Search Results

1

Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Cheng AL, et al. Anticancer Res. 2001 Jul-Aug;21(4B):2895-900. Anticancer Res. 2001. PMID: 11712783 Clinical Trial.

2

Tamoxifen enhances the chemosensitivity of bladder carcinoma cells.

Pu YS, Hsieh TS, Tsai TC, Cheng AL, Hsieh CY, Su IJ, Lai MK. Pu YS, et al. Among authors: cheng al. J Urol. 1995 Aug;154(2 Pt 1):601-5. doi: 10.1097/00005392-199508000-00078. J Urol. 1995. PMID: 7609145

3

Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study.

Yeh KH, Cheng AL, Chen YC, Chen BR, Lee WJ, Lin JT, Lee PH, Chang KJ, Wang CH, Wang TH. Yeh KH, et al. Among authors: cheng al. J Formos Med Assoc. 1994 Jan;93(1):20-4. J Formos Med Assoc. 1994. PMID: 7915575

4

Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study.

Cheng AL, Su IJ, Chen CC, Tien HF, Lay JD, Chen BR, Pu YS, Hong RL, Shen MC, Wang CH, et al. Cheng AL, et al. J Clin Oncol. 1994 Jun;12(6):1185-92. doi: 10.1200/JCO.1994.12.6.1185. J Clin Oncol. 1994. PMID: 8201381 Clinical Trial.

5

Clinicopathologic characteristics of Helicobacter pyloric seropositive gastric adenocarcinomas.

Lee WJ, Lin JT, Lee WC, Shun CT, Hong RL, Cheng AL, Lee PH, Wei TC, Chen KM. Lee WJ, et al. Among authors: cheng al. J Clin Gastroenterol. 1995 Oct;21(3):203-7. doi: 10.1097/00004836-199510000-00007. J Clin Gastroenterol. 1995. PMID: 8648053

6

Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response.

Pu YS, Tsai TC, Cheng AL, Tsai CY, Tseng NF, Su IJ, Hsieh CY, Lai MK. Pu YS, et al. Among authors: cheng al. J Urol. 1996 Jul;156(1):271-5. J Urol. 1996. PMID: 8648821

7

Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.

Pu YS, Hsieh TS, Cheng AL, Tseng NF, Su IJ, Hsieh CY, Lai MK, Tsai TC. Pu YS, et al. Among authors: cheng al. Br J Urol. 1996 Jan;77(1):76-85. doi: 10.1046/j.1464-410x.1996.82712.x. Br J Urol. 1996. PMID: 8653321

8

Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue: clinicopathologic analysis of 19 cases.

Chiang IP, Wang HH, Cheng AL, Lin JT, Su IJ. Chiang IP, et al. Among authors: cheng al. J Formos Med Assoc. 1996 Nov;95(11):857-65. J Formos Med Assoc. 1996. PMID: 8990774

9

Infrequent hMSH2 mutations in sporadic gastric adenocarcinoma with microsatellite instability.

Wu MS, Sheu JC, Shun CT, Lee WJ, Wang JT, Wang TH, Cheng AL, Lin JT. Wu MS, et al. Among authors: cheng al. Cancer Lett. 1997 Jan 30;112(2):161-6. doi: 10.1016/s0304-3835(96)04565-x. Cancer Lett. 1997. PMID: 9066723

10

MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer.

Hsu C, Yeh KH, Hong RL, Yang CH, Lin MT, Chen YC, Cheng AL. Hsu C, et al. Among authors: cheng al. J Formos Med Assoc. 1997 Mar;96(3):185-8. J Formos Med Assoc. 1997. PMID: 9080756

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

828 results

Search Page

Filters